JPWO2020210768A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210768A5 JPWO2020210768A5 JP2021560665A JP2021560665A JPWO2020210768A5 JP WO2020210768 A5 JPWO2020210768 A5 JP WO2020210768A5 JP 2021560665 A JP2021560665 A JP 2021560665A JP 2021560665 A JP2021560665 A JP 2021560665A JP WO2020210768 A5 JPWO2020210768 A5 JP WO2020210768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- egfr
- group
- car
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001301 EGF receptor Human genes 0.000 claims description 148
- 108060006698 EGF receptor Proteins 0.000 claims description 148
- 239000000427 antigen Substances 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 102220198019 rs149840192 Human genes 0.000 claims description 32
- 230000003834 intracellular effect Effects 0.000 claims description 27
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 102220198020 rs139236063 Human genes 0.000 claims description 16
- 102000001708 Protein Isoforms Human genes 0.000 claims description 14
- 108010029485 Protein Isoforms Proteins 0.000 claims description 14
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 102000002698 KIR Receptors Human genes 0.000 claims description 12
- 108010043610 KIR Receptors Proteins 0.000 claims description 12
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 4
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000022534 cell killing Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000002220 organoid Anatomy 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025044320A JP2025102823A (ja) | 2019-04-12 | 2025-03-19 | 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833456P | 2019-04-12 | 2019-04-12 | |
| US62/833,456 | 2019-04-12 | ||
| US201962892343P | 2019-08-27 | 2019-08-27 | |
| US62/892,343 | 2019-08-27 | ||
| PCT/US2020/027859 WO2020210768A1 (en) | 2019-04-12 | 2020-04-11 | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025044320A Division JP2025102823A (ja) | 2019-04-12 | 2025-03-19 | 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526856A JP2022526856A (ja) | 2022-05-26 |
| JPWO2020210768A5 true JPWO2020210768A5 (https=) | 2022-09-30 |
| JP2022526856A5 JP2022526856A5 (https=) | 2022-09-30 |
Family
ID=72751475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560665A Pending JP2022526856A (ja) | 2019-04-12 | 2020-04-11 | 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 |
| JP2025044320A Pending JP2025102823A (ja) | 2019-04-12 | 2025-03-19 | 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025044320A Pending JP2025102823A (ja) | 2019-04-12 | 2025-03-19 | 臨床的に意義のあるｅｇｆｒ変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体（ｃａｒ）を含む、組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220184129A1 (https=) |
| EP (1) | EP3952885A4 (https=) |
| JP (2) | JP2022526856A (https=) |
| AU (1) | AU2020272074A1 (https=) |
| WO (1) | WO2020210768A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4259648A4 (en) * | 2020-12-08 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric anti-EGFR antigen receptors |
| EP4344409A4 (en) * | 2021-07-01 | 2025-05-21 | Duke University | D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same |
| US20240285757A1 (en) * | 2021-08-06 | 2024-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing car t cell efficacy through the engineered secretion of c. perfringens neuraminidase |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2013327136A1 (en) * | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| EP3447072A3 (en) * | 2013-03-05 | 2019-05-22 | Baylor College of Medicine | Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2014201378A1 (en) * | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| JP6682509B2 (ja) * | 2014-05-14 | 2020-04-15 | カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球 |
| WO2017027291A1 (en) * | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| SG11201805449PA (en) * | 2015-12-28 | 2018-07-30 | Novartis Ag | Methods of making chimeric antigen receptor -expressing cells |
| MY209117A (en) * | 2016-04-15 | 2025-06-23 | Novartis Ag | Compositions and methods for selective protein expression |
| WO2017181101A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric alloantigen receptor t cells |
| WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| CN110564749B (zh) * | 2018-06-05 | 2024-01-05 | 上海恒润达生生物科技股份有限公司 | 靶向egfr的嵌合抗原受体及其用途 |
| US20230158071A1 (en) * | 2018-12-07 | 2023-05-25 | Crage Medical Co., Limited | Tumor combined immunotherapy |
-
2020
- 2020-04-11 AU AU2020272074A patent/AU2020272074A1/en active Pending
- 2020-04-11 JP JP2021560665A patent/JP2022526856A/ja active Pending
- 2020-04-11 EP EP20787846.3A patent/EP3952885A4/en active Pending
- 2020-04-11 US US17/602,949 patent/US20220184129A1/en active Pending
- 2020-04-11 WO PCT/US2020/027859 patent/WO2020210768A1/en not_active Ceased
-
2025
- 2025-03-19 JP JP2025044320A patent/JP2025102823A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP6650537B2 (ja) | 抗ｃｔｌａ−４抗体 | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| RU2744959C2 (ru) | Новые анти-pd-l1 антитела | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| KR102291971B1 (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| JP2020520665A5 (https=) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2019536470A5 (https=) | ||
| JP2019509055A (ja) | 多特異性免疫調節抗原結合構築物 | |
| JP2019517773A (ja) | 抗ｌａｇ−３抗体 | |
| JP7815595B2 (ja) | 抗ｍｄｒ１抗体およびその使用 | |
| CA2974302C (en) | Inhibitors of the interaction between clec14a and multimerin-2 for inhibition of angiogenesis | |
| JP2022526856A5 (https=) | ||
| JP2023517794A (ja) | 抗ｔｎｆｒ２抗体及びその使用 | |
| JPWO2020210768A5 (https=) | ||
| JP7753401B2 (ja) | ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック | |
| JPWO2022217019A5 (https=) | ||
| JP7747741B2 (ja) | 抗ａｂｃｃ１抗体及びその使用 | |
| CN119285769A (zh) | 多特异性抗体及其医药用途 | |
| JP2025503446A (ja) | Ｔｉｇｉｔ抗体及びその用途 | |
| CN120904324A (zh) | 抗cd28抗体及其用途 | |
| KR20220143904A (ko) | 사람 4-1bb 항진제 항체 및 이의 사용 방법 | |
| JPWO2023004326A5 (https=) | ||
| JPWO2023168326A5 (https=) |